Agenus Inc
AGEN3.500USD
+0.060+1.74%
交易中 （美东）报价延迟15分钟
114.85M总市值
亏损市盈率 TTM
关于 Agenus Inc 公司
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc简介
公司代码AGEN
公司名称Agenus Inc
上市日期Feb 04, 2000
CEOArmen (Garo H)
员工数量316
证券类型Ordinary Share
年结日Feb 04
公司地址3 Forbes Rd
城市LEXINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02421-7305
电话17816744400
网址https://agenusbio.com/
公司代码AGEN
上市日期Feb 04, 2000
CEOArmen (Garo H)
Agenus Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
地区USD
名称
营收
占比
United States
25.16M
97.95%
Rest of World
526.00K
2.05%
业务
地区
业务USD
名称
营收
占比
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
股东统计
更新时间: 12月20日 周六
更新时间: 12月20日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.56%
Invus Public Equities Advisors, LLC
3.13%
B. Riley Financial, Inc
2.23%
Morgan Stanley & Co. LLC
1.45%
BlackRock Institutional Trust Company, N.A.
1.38%
其他
84.26%
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.56%
Invus Public Equities Advisors, LLC
3.13%
B. Riley Financial, Inc
2.23%
Morgan Stanley & Co. LLC
1.45%
BlackRock Institutional Trust Company, N.A.
1.38%
其他
84.26%
股东类型
持股股东
占比
Investment Advisor
18.38%
Investment Advisor/Hedge Fund
4.70%
Hedge Fund
3.22%
Research Firm
2.98%
Individual Investor
1.70%
Pension Fund
0.36%
Bank and Trust
0.03%
其他
68.64%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
2023Q3
382
11.27M
62.51%
+267.62K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
2.53M
7.95%
-16.81K
-0.66%
Jun 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.34%
+564.25K
+112.85%
Jun 30, 2025
B. Riley Financial, Inc
756.96K
2.38%
+756.96K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
719.75K
2.26%
+350.35K
+94.84%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
489.68K
1.54%
-1.12M
-69.54%
Jun 30, 2025
BofA Global Research (US)
420.68K
1.32%
+220.33K
+109.97%
Jun 30, 2025
Armen (Garo H.)
338.69K
1.06%
+7.51K
+2.27%
Sep 19, 2025
Millennium Management LLC
504.51K
1.58%
+504.51K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
317.41K
1%
-226.73K
-41.67%
Jun 30, 2025
Walleye Capital LLC
198.29K
0.62%
+198.29K
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0%
iShares Russell 3000 ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
SPDR Portfolio MSCI Global Stock Market ETF
占比0%
Global X Russell 2000 ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
公告日期
类型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
常见问题
Agenus Inc的前五大股东是谁？
Agenus Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：2.53M，占总股份比例：7.95%。
Invus Public Equities Advisors, LLC持有股份：1.06M，占总股份比例：3.34%。
B. Riley Financial, Inc持有股份：756.96K，占总股份比例：2.38%。
Morgan Stanley & Co. LLC持有股份：719.75K，占总股份比例：2.26%。
BlackRock Institutional Trust Company, N.A.持有股份：489.68K，占总股份比例：1.54%。
The Vanguard Group, Inc.持有股份：2.53M，占总股份比例：7.95%。
Invus Public Equities Advisors, LLC持有股份：1.06M，占总股份比例：3.34%。
B. Riley Financial, Inc持有股份：756.96K，占总股份比例：2.38%。
Morgan Stanley & Co. LLC持有股份：719.75K，占总股份比例：2.26%。
BlackRock Institutional Trust Company, N.A.持有股份：489.68K，占总股份比例：1.54%。
Agenus Inc的前三大股东类型是什么？
Agenus Inc 的前三大股东类型分别是：
The Vanguard Group, Inc.
Invus Public Equities Advisors, LLC
B. Riley Financial, Inc
The Vanguard Group, Inc.
Invus Public Equities Advisors, LLC
B. Riley Financial, Inc
有多少机构持有Agenus Inc(AGEN)的股份？
截至2025Q4，共有304家机构持有Agenus Inc的股份，合计持有的股份价值约为9.95M，占公司总股份的37.38%。与2025Q3相比，机构持股有所增加，增幅为-4.01%。
哪个业务部门对Agenus Inc的收入贡献最大？
在FY2025Q2，Non-cash royalty revenue业务部门对Agenus Inc的收入贡献最大，创收24.83M，占总收入的96.65%。
